Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hamsa-1 in Metastatic Castration Resistant Prostate Cancer
NCT00684970Phase 2Unknown
- Sponsor
- Tiltan Pharma
- Start
- Mar 2009
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TL-118 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tiltan Pharma. Primary endpoint: Progression Free Survival at 3 years. Status: unknown.
02
Drugs
TL-118
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00684970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684970.